Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mifepristone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 10/20 | 1.00 |
| ▸ | PGR known ✓ | P06401 | 10/20 | 1.00 |
| ▸ | AR | P10275 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mifepristone SCHEMBL19236544 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4CYP2D6 | |
| Mifepristone SCHEMBL19100510 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4CYP2D6 | |
| Mifepristone SCHEMBL13840946 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4CYP2D6 | |
| Mifepristone SCHEMBL16087 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4CYP2D6 | |
| Mifepristone SCHEMBL10622661 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4CYP2D6 | |
| Mifepristone SCHEMBL10625406 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4CYP2D6 | |
| Mifepristone SCHEMBL10607607 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4CYP2D6 | |
| Mifepristone SCHEMBL918725 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4CYP2D6 | |
| Mifepristone SCHEMBL20769786 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4CYP2D6 | |
| Mifepristone SCHEMBL14870641 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261693-A1 | METHOD FOR TREATING CUSHING'S SYNDROME | LABORATOIRE HRA PHARMA (FR) | 2010-10-14 | — | — | US | disclosed |
| US-20100261693-A1 | METHOD FOR TREATING CUSHING'S SYNDROME | LABORATOIRE HRA PHARMA (FR) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261693-A1 | METHOD FOR TREATING CUSHING'S SYNDROME | MC2R, CRH, CRHR2 | NR3C1 9/4885PGR 125/4885AR 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.